New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
List view / Grid view
Sarah Cannon Research Institute (SCRI)
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...